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Atherosclerosis and related cardiovascular dis-
eases represent a state of infl  ammation  and 
heightened oxidative stress characterized by the 
accumulation of macrophages and products of 
lipid and protein oxidation in aff  ected blood 
vessels. Abundant data support the oxidative 
modifi  cation hypothesis of atherosclerosis, ac-
cording to which oxidation of low-density lip-
oprotein is an early event in and contributes to 
atherogenesis (1). However, this hypothesis has 
been challenged recently by the failure of anti-
oxidants, in particular vitamin E, to reduce dis-
ease progression and clinical events in patients 
at risk of or with established atherosclerosis (2). 
Various reasons may contribute to this failure. 
For example, there is little direct evidence that 
vitamin E acts as an antioxidant in human 
blood vessels (2, 3), and this antioxidant does 
not eff   ectively scavenge oxidants like hypo-
chlorite that have been implicated in causing 
oxidative damage relevant to atherogenesis 
(2–4). Also, the subjects enrolled in the clinical 
trials of vitamin E were not selected for evidence 
of increased oxidative stress, and this could im-
pact on the eff  ectiveness of antioxidants (5).
An exception to the failure of antioxidants 
to reduce atherosclerotic disease is probucol, a 
rarely used cholesterol-lowering drug com-
posed of a diphenol linked by an isopro  pylidene 
dithio “bridge” (Table I). In humans, probucol 
inhibits atherosclerosis in the carotid artery 
(6) and neointimal proliferation after coronary 
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Oxidative stress is implicated in atherogenesis, yet most clinical trials with antioxidants, 
particularly vitamin E, have failed to protect against atherosclerotic diseases. A striking 
exception is probucol, which retards atherosclerosis in carotid arteries and restenosis of 
coronary arteries after angioplasty. Because probucol has in vitro cellular-protective effects 
independent of inhibiting lipid oxidation, we investigated the mode of action of probucol 
in vivo. We used three models of vascular disease: apolipoprotein E–defi  cient mice, a model 
of atherosclerosis; rabbit aortic balloon injury, a model of restenosis; and carotid injury in 
obese Zucker rats, a model of type 2 diabetes. Unexpectedly, we observed that the phenol 
moieties of probucol were insuffi  cient, whereas its sulphur atoms were required for protec-
tion. Probucol and its sulphur-containing metabolite, but not a sulphur-free phenolic 
analogue, protected via cell-specifi  c effects on inhibiting macrophage accumulation, stim-
ulating reendothelialization, and inhibiting vascular smooth muscle cell proliferation. These 
processes were mediated via induction of heme oxygenase-1 (HO-1), an activity not shared 
by vitamin E. Our fi  ndings identify HO-1 as the molecular target of probucol. They indicate 
2-electron rather than radical (1-electron) oxidants as important contributors to athero-
genesis, and point to novel lead compounds for therapeutic intervention against atheroscle-
rotic diseases.
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  angioplasty with (7) and without (8) stent deployment. Simi-
larly, probucol retards atherosclerosis (9) and intimal thicken-
ing after balloon injury in animals (10). Several previous 
studies have addressed the anti-atherosclerotic activity of pro-
bucol-like diphenols (Table II). We interpret the outcome of 
these studies as evidence for the notion that the sulfur atoms 
are required, whereas the two phenol groups may not be suf-
fi  cient for protection. In the present study, we tested this hy-
pothesis by comparing the ability of diphenols that contain 
(i.e., probucol and probucol dithiobisphenol) or do not con-
tain the sulfur atoms (probucol bisphenol; Table I) to protect 
against atherosclerotic vascular disease.
RESULTS
In apolipoprotein E–defi  cient (Apoe−/−) mice, a commonly 
used model of hypercholesterolemia-induced atherosclerosis 
(11), probucol strongly inhibits disease in the descending aorta 
(9, 12). To determine the structural requirements underlying 
this activity, we compared the anti-atherosclerotic eff  ect of di-
etary supplementation with 1% (wt/wt) probucol with that of 
0.02% probucol dithiobisphenol or 0.02% probucol bisphenol 
(Table I) in Apoe−/− mice fed a high-fat diet for 5 mo. These 
compounds were chosen because we wished to test the hy-
pothesis that the sulfur atoms (present in probucol and probu-
col dithiobisphenol, but absent in probucol bisphenol) are 
required, whereas the two phenol groups (present in all three 
compounds) may not be suffi   cient for anti-atherosclerotic ac-
tivity (Table II). The dosages used were chosen based on a 
previous study (13). They resulted in comparable total aortic 
concentration of the respective drug in the probucol and pro-
bucol dithiobisphenol groups (21.8 ± 8.4 and 7.1 ± 1.4 
nmol/mg protein, respectively; P = 0.109). Drug levels were 
somewhat higher in the probucol bisphenol group (92.8 ± 18 
nmol/mg protein; P = 0.023 and 0.009 for probucol bisphe-
nol vs. probucol and probucol dithio  bisphenol, respectively; 
n = 3 pools of fi  ve aortas per pool for each treatment).
Probucol strongly decreased atherosclerosis at all three 
aortic sites examined (Fig. 1, A and B). Probucol dithiobi-
sphenol showed comparable effi   cacy, whereas probucol bi-
sphenol had no signifi  cant eff  ect (Fig. 1, A and B). Unlike 
probucol, however, probucol dithiobisphenol did not lower 
plasma cholesterol (Fig. 1 C) or high-density lipoprotein 
(Fig. 1 D), an undesirable side eff  ect of probucol (7) and the 
reason why the drug was withdrawn from the pharmaceutical 
market in the U.S. Consistent with their anti-atherosclerotic 
activity, probucol and probucol dithiobisphenol, but not 
probucol bisphenol, decreased the aortic content of neutral 
lipids (cholesterylesters plus triglycerides; Fig. 1 E), but the 
hydroperoxides of these lipids were not aff  ected (Fig. 1 F). 
Inhibition of atherosclerosis was associated with fewer mac-
rophages (Fig. 1, B and G) and proliferating cells (Fig. 1 H).
We next performed a similar structure-function study in 
a rabbit model of intimal hyperplasia in response to injury, 
using the same drug dosage regime. Animals were matched 
for baseline plasma cholesterol and fed a limited amount 
(100 g/day) of standard diet ± the test drug to control for 
probucol’s cholesterol-lowering eff   ect. Rabbits treated for 
9 wk with control chow supplemented with 1% (wt/wt) pro-
bucol, 0.02% probucol dithiobisphenol, or 0.02% probucol 
bisphenol had indistinguishable concentrations of the respec-
tive drug in the injured aorta. Thus, the amounts of total drug 
in the vessel wall were 663 ± 114, 235 ± 64, and 614 ± 258 
Table I.  Structure of probucol and its analogues used 
in this study
Compound Structure One-electron 
potential (mV)
Probucol 545
Probucol 
 dithiobisphenol
417
Probucol bisphenol 307
Redox potentials for the one-electron oxidation of the compounds listed were 
determined for analytically pure samples of probucol, probucol dithiobisphenol, and 
probucol dithiobisphenol by cyclic voltammetry using a BAS electrochemical 
analyzer as described previously (reference 55). In brief, each compound (fi  nal 
concentration, 1 mM) was dissolved in deoxygenated, redistilled dimethylsulfoxide 
(Sigma-Aldrich), containing 200 mM tetrabutylammonium tetrafl  uoroborate 
(Sigma-Aldrich) as the supporting electrolyte. Cyclic voltammetry was performed 
with the scan rate set to 100 mVs−1 sweeping the scan range 0 to 1.5 V at 20 °C.
Table II.  Chemical structure of probucol analogues used 
in previous atherosclerosis intervention studies
Active Inactive
MDL 29,311 (65) BM 15.0639 (36)
MDL 27,272 (65) Probucol bisphenol (13)
AGI-1067 (37)
The compounds shown are separated into antioxidants that inhibit (active) and 
those that do not inhibit atherosclerosis (inactive). Anti-atherosclerotic activity was 
tested in Watanabe heritable hyperlipidemic rabbits, except for AGI-1067, which was 
used in Apoe−/− mice and in low-density lipoprotein receptor–null mice. Note that 
probucol analogues without sulphur atoms are inactive, whereas analogues with 
altered “dithio-bridge” or blocked phenolic group retain anti-atherosclerotic activity.JEM VOL. 203, April 17, 2006  1119
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pmol per mg protein for probucol, probucol dithiobisphenol, 
and probucol bisphenol, respectively (n = 6 per group, P > 0.05 
for all comparisons). Similar to the mouse atherosclerosis 
study, rabbits receiving probucol or probucol dithiobisphenol, 
but not probucol bisphenol, were protected from disease, as 
assessed by the intima-to-media ratio (Fig. 2, A and B). 
In this model, the vessel contents of both nonoxidized (Fig. 
2 C) and oxidized neutral lipids (Fig. 2 D) remained unaltered, 
Figure 1.  Probucol and probucol dithiobisphenol, but not probucol 
bisphenol, inhibit atherosclerosis in Apoe−/− mice. (A) Lesion area in 
animals treated with probucol (P, ◆), probucol dithiobisphenol (DTBP, ■), 
or probucol bisphenol (BP, ▲) compared with control (Ctrl, ○). n = 10 for 
each site, each using two, six, and three serial sections for arch, thoracic 
(TA), and abdominal aorta (AA), respectively. (B) Representative cross sec-
tions of abdominal aorta from control and the three treatment groups 
stained for macrophages indicating respective lesion size. Bar, 25 μm. 
(C) Plasma cholesterol, n = 10. (D) FPLC chromatograms of lipoproteins 
from pooled plasma (n = 10) of control, probucol, probucol dithiobisphe-
nol, and probucol bisphenol animals. (E) Neutral lipids (NL, comprised of 
cholesterylesters and triglycerides) and (F) their hydroperoxides (LOOH) 
standardized to NL. n = 3 pools of fi  ve aortas per pool. (G) Average 
lesion area covered by Mac-3+ cells (i.e., macrophages) and (H) PCNA+ 
(i.e., proliferating) cells in the arch, thoracic, and abdominal aorta as 
compared with corresponding control. n = 3 for each site (three serial 
  sections/site). *, P < 0.05; **, P < 0.01; ***, P < 0.001 compared 
with control.
Figure 2.  Probucol and probucol dithiobisphenol, but not probucol 
bisphenol, inhibit intimal hyperplasia in rabbits in response to vessel 
injury. (A) Representative Verhoeff’s hematoxylin-stained cross sections. 
Bar, 1,000 μm. (B) Intima-to-media ratio of vessels from control and 
drug-treated rabbits 6 wk after aortic balloon injury (eight serial sections 
per aortic segment, 100 μm apart). (C) Neutral lipids and (D) their hydro-
peroxides. (E) Time-dependent changes in plasma cholesterol of control 
rabbits or animals treated with probucol, probucol dithiobisphenol, or 
probucol bisphenol. All results are from six rabbits per group. Symbols 
and abbreviations are as described in the legend to Fig. 1.1120  REDOX-ACTIVE COMPOUNDS AND ATHEROSCLEROTIC DISEASE | Wu et al.
and probucol and probucol bisphenol, but not probucol 
  dithiobisphenol, signifi  cantly decreased plasma cholesterol 
(Fig. 2 E). Thus, results from the two animal models indicate 
that the protective activity seen with probucol and probucol 
dithiobisphenol is independent of both cholesterol lowering 
and inhibition of lipid oxidation.
Reendothelialization is a key repair process in response to 
arterial injury, and it is promoted by probucol (14). 6 wk after 
injury, the injured aortic surface is partially covered by endo-
thelium regenerating from branch orifi  ces (Fig. 3 A). Com-
pared with control, probucol and probucol dithiobisphenol, 
but not probucol bisphenol, signifi  cantly enhanced the extent 
of this reendothelialization (Fig. 3 B) and decreased the intima-
to-media ratio signifi  cantly at these reendothelialized sites (Fig. 
3 C). Functional studies using aortic rings taken adjacent to 
branches showed that probucol and probucol dithiobisphenol, 
but not probucol bisphenol, enhanced endothelium-dependent 
relaxation (Fig. 3 D). This was associated with increased aortic 
content of guanosine 3′,5′-cyclic monophosphate in response 
to acetylcholine (Fig. 3 E), indicating enhanced nitric oxide 
synthase activity. None of the compounds aff  ected endothe-
lium-independent relaxation induced by sodium nitroprusside 
(Fig. 3 F). Thus, probucol dithiobisphenol, but not probucol 
bisphenol, mimics the eff  ect of probucol on promoting the re-
generation of functional endothelium.
Increasing evidence points to a key role of heme oxygen-
ase-1 (HO-1) in the control of intimal hyperplasia (15). Previ-
ous studies (15) established that vascular injury transiently 
induces HO-1, and in our rabbit balloon injury model, HO-1 
mRNA and heme oxygenase activity are induced maximally 
on day 4 after injury, with HO-1 mRNA and enzyme activity 
returning to baseline level on day 7 (16). Immunohistochem-
istry performed on aortas 4 d after injury showed induction of 
HO-1 in the media close to the luminal side in animals treated 
with probucol or probucol dithiobisphenol, but not probucol 
bisphenol (Fig. 4 A). Enhanced HO-1   expression was accom-
panied by signifi  cant increases in tissue levels of HO-1 mRNA 
(Fig. 4 B) and heme oxygenase activity (Fig. 4 C).
Induction of HO-1 in vascular smooth muscle cells is linked 
to enhanced apoptosis resulting in decreased proliferation (17). 
Indeed, probucol and probucol dithiobisphenol, but not 
  probucol bisphenol, signifi  cantly enhanced early apoptosis,   
Figure 3.  Probucol and probucol dithiobisphenol, but not probu-
col bisphenol, promote functional reendothelialization in rabbit 
aortas after injury. (A) Representative longitudinal section with branch 
orifi  ce (bar, 500 μm) showing denuded and CD-31+ reendothelialized 
aortic surface (red staining) distant and close to the branch orifi  ce, re-
spectively (bar, 25 μm), 6 wk after injury. (B) Reendothelialization as-
sessed by the length (mm) of section covered by CD-31+ cells from the 
branch orifi  ce for each group 6 wk after injury (three to six serial sec-
tions per segment, 100 μm apart). (C) Intima-to-media ratio determined 
by dividing the intimal over the medial area covered by an intact endo-
thelium distal to the branch of the third lumbar artery (three to six serial 
sections per segment, 100 μm apart). (D–F) Aortic rings obtained proxi-
mally to the second lumbar arteries of the four groups were used for 
vessel ring studies and examined for relaxation after preconstriction in 
response to acetylcholine (ACh, D) and sodium nitroprusside (SNP, E), 
with results expressed as percentage of maximal relaxation. (F) Content 
of guanosine 3′,5′-cyclic monophosphate (cGMP) in aortic rings 
(obtained distally to the second lumbar arteries of the four groups) 
exposed to acetylcholine after preincubation in the presence of 3-
isobutyl-1-methylxanthine and inhibitor of phosphodiesterases. All 
results are from six rabbits per group. Symbols and abbreviations are 
as described in the legend to Fig. 1.JEM VOL. 203, April 17, 2006  1121
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i.e., at day 4 (Fig. 4 D) but not day 42 after balloon injury 
(Fig. 4 E) as assessed by the number of vascular cells positive 
for terminal deoxynucleotidyl transferase-mediated deoxy-
uridine triphosphate nick end labeling (TUNEL). Increased 
apoptosis was associated with a signifi  cant late decrease in cell 
proliferation, i.e., at day 42 (Fig. 4 G) but not day 4 after injury 
(Fig. 4 F) as assessed by the proportion of cells positive for 
proliferating cell nuclear antigen (PCNA). Immunostaining 
for HO-1 was no longer detected in damaged vessels 42 d 
  after injury (not depicted).
The oxidative modifi  cation hypothesis of atherosclerosis 
has been challenged recently by the failure of vitamin E, 
  either alone or in combination with vitamin C, selenium, or 
β-carotene, to reduce disease progression and clinical events 
in patients at risk of or with established atherosclerosis (2). As 
vitamin E administration blocks rather than induces HO-1 
in vivo (18–20), we therefore next compared probucol with 
vitamin E in the rabbit aortic balloon injury model. Unlike 
probucol, vitamin E failed to induce HO-1 in vascular smooth 
muscle cells in vitro (Fig. 5 A). This was refl  ected by a lack of 
ability of the vitamin to promote reendothelialization (Fig. 5 B) 
and to inhibit intimal hyperplasia (Fig. 5 C). These results 
contrast to the cellular eff  ects of vitamin E and probucol.
To directly link HO-1 induction with inhibition of inti-
mal hyperplasia, we repeated the intervention with probucol 
and probucol dithiobisphenol in the rabbit aortic balloon injury 
model with animals treated with tin protoporphyrin-IX, an 
Figure 4.  Probucol and probucol dithiobisphenol, but not probucol 
bisphenol, induce HO-1 in balloon-injured rabbit aortas, and this is 
related to subsequent apoptosis and vascular smooth muscle cell 
proliferation. (A) Representative cross sections taken from control and 
treated rabbits 4 d after aortic balloon injury and stained for HO-1. Bar, 
25 μm. n = 4 for each treatment (three serial sections/aorta). (B) HO-1 
mRNA and (C) heme oxygenase activity in aortas taken from control and 
treated rabbits 4 d after injury. n = 8 per treatment. (D–G) Apoptosis and 
cell proliferation were assessed by the proportion of cells in correspond-
ing aortic sections (n = 3 per aorta) obtained from differently treated 
animals (n = 4–6 per group) staining positive for TUNEL and PCNA, 
  respectively, as described in Materials and methods. (D) Apoptosis 4 d 
after injury. (E) Apoptosis 42 d after injury. (F) Proliferation 4 d after 
injury. (G) Proliferation 42 d after injury. Symbols and abbreviations are 
as described in the legend to Fig. 1.
Figure 5.  Vitamin E fails to inhibit intimal hyperplasia and does 
not promote reendothelialization or induce HO-1. (A) HO-1 mRNA 
assessed by real-time RT-PCR in rabbit aortic smooth muscle cells cul-
tured for 24 h in the presence of vehicle (control), 50 μM probucol, or 
50 μM α-tocopherol (VE). (B) Reendothelialization assessed by Evans 
blue staining for the three groups of rabbits shown in A 3 wk after 
  injury. (C) Intima-to-media ratio of vessels from control rabbits and 
animals treated with probucol or α-tocopheryl acetate (VE) (n = 6 per 
group) 3 wk after aortic balloon injury (fi  ve serial sections per aortic 
segment, 100 μm apart). Results show mean ± SEM of a triplicate ex-
periment performed twice with similar results obtained in both experi-
ments. Symbols and abbreviations are as described in the legend to Fig. 1.1122  REDOX-ACTIVE COMPOUNDS AND ATHEROSCLEROTIC DISEASE | Wu et al.
established inhibitor of heme oxygenase (21). In these rabbits, 
probucol and probucol dithiobisphenol no longer attenuated 
intimal hyperplasia when compared with control animals that 
received tin protoporphyrin only (Fig. 6 A). Similarly, inhi-
bition of heme oxygenase abolished the ability of probucol 
and probucol dithiobisphenol to promote reendothelializa-
tion (Fig. 6 B) and inhibit smooth muscle cell proliferation 
(Fig. 6 C). Collectively, these fi  ndings suggest that HO-1 is a 
molecular target of the vascular-protective eff   ects of the 
  redox-active compound probucol and its active metabolite 
probucol dithiobisphenol.
To exclude the possibility that HO-1 induction as the 
underlying mode of probucol’s protection is limited to rab-
bits, we examined the eff  ect of heme oxygenase blockade on 
the action of probucol in a second species. We used carotid 
balloon injury (22) in obese Zucker rats as an animal model 
of type 2 diabetic vascular restenosis. The obese Zucker rat 
has an autosomal-recessive inheritance resulting in hypergly-
cemia, insulin resistance, and hyperlipidemia (23), and thus 
simulates human type 2 diabetes. Also, in analogy to the in-
creased restenosis rate in humans with type 2 diabetes (24), 
the intimal area of carotid arteries 2 wk after injury was sig-
nifi  cantly greater in obese compared with lean Zucker rats 
that are phenotypically normal and act as control (Table III). 
There was also a comparatively smaller but signifi  cant   increase 
in medial area in obese rats. As a result, the intima-to-media 
ratio was increased substantially in obese compared with lean 
rats (Table III).
Probucol (1%, wt/wt) treatment had no signifi  cant eff  ect 
on body weight, fasting blood glucose, and hemoglobin gly-
cosylation, or plasma triglycerides and nonesterifi  ed choles-
terol (not depicted). Probucol also had no eff  ect on plasma 
concentrations of F2-isoprostanes, a commonly used marker 
of in vivo lipid oxidation (25), whether expressed in absolute 
terms (2.05 ± 0.17 vs. 1.96 ± 0.27 ng/ml for obese vs. obese 
plus probucol, respectively) or corrected for the parent lipid, 
arachidonic acid (8.0 ± 4.4 vs. 4.3 ± 0.6 pg/μg for obese vs. 
obese plus probucol, respectively). These results suggest that 
in this model, probucol did not act as an inhibitor of lipid 
oxidation. Despite this, however, probucol signifi  cantly in-
hibited intimal hyperplasia as measured by the decrease in 
both intimal area and intima-to-media ratio   (Table III). This 
protective eff  ect was not due to vascular   remodeling, as pro-
bucol did not aff  ect medial area (Table III) and the length of 
the external elastic lamina (not depicted). Rather, probucol 
signifi  cantly increased reendothelialization (Table III), as ob-
served in the rabbit model. Lean rats at the same time point 
were completely reendothelialized.   Enhancement of reendo-
thelialization of injured arteries by probucol was associated 
with increased expression of HO-1, as seen with immuno-
histochemistry (not depicted), as well as a decrease in total 
and proliferating cells in the neointima (Table III). Finally, 
and similar to the rabbit restenosis model, the heme  oxygenase 
inhibitor, tin protoporphyrin, signifi   cantly attenuated the 
ability of probucol to decrease intimal area and the intima-to-
media ratio, and this was associated with a decrease in the ex-
tent of reendothelialization (Table IV). These results confi  rm 
that blockade of heme oxygenase prevents the benefi  cial ac-
tivities of probucol independently of the animal model used.
DISCUSSION
Here we identify a novel structural element and mode of ac-
tion by which the redox-active compound probucol inhibits 
Figure 6.  HO-1 is the molecular target for probucol and probucol 
dithiobisphenol. All animals (n = 6 per group) received tin(IV) protopor-
phyrin IX dichloride to block heme oxygenase. (A) Intima-to-media ratio 
of vessels 6 wk after aortic balloon injury (eight serial sections per seg-
ment, 100 μm apart). (B) Reendothelialization assessed by the length 
(mm) of section covered by CD-31+ cells from the branch orifi  ce (three to 
six serial sections per segment, 100 μm apart), and (C) cell proliferation is 
indicated by PCNA+ cells 6 wk after injury. Symbols and abbreviations are 
as described in the legend to Fig. 1.
Table III.  Morphometry of carotid artery after balloon injury 
of lean and obese Zucker rats
Lean
(n = 9)
Obese
(n = 9)
Obese + 
probucol
(n = 9)
Intimal area (mm2) 0.01 ± 0.0 0.12 ± 0.01a 0.05  ± 0.01b
Medial area (mm2) 0.13 ± 0.01 0.16 ± 0.0a 0.15 ± 0.01
Intima-to-media ratio 0.08 ± 0.03 0.74 ± 0.05a 0.28 ± 0.06b
Reendothelialization (%)  100 ± 0    42 ± 8a    80 ± 13b
Total intimal cells (number 
  per high powered fi  eld)
       ND  237 ± 13    78 ± 28b
PCNA+-cells in intima        ND    50 ± 17    11 ± 7b
Probucol (1%, wt/wt) was administered for 4 wk, with carotid balloon injury 
performed after 2 wk and carotid artery morphometry, reendothelialization, and 
intimal cell proliferation assessed at the end of the 4-wk intervention as described 
in Materials and methods. Total and PCNA+ cells were assessed as the number 
of cells per high power fi  eld (average of three fi  elds). Values are mean ± SEM. 
ND, not detected.
aP < 0.05 versus lean.
bP < 0.05 versus obese.JEM VOL. 203, April 17, 2006  1123
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atherosclerotic vascular disease in three diff  erent models of vas-
cular injury: the Apoe−/− mouse model of atherosclerosis, the 
rabbit arterial injury model of restenosis, and the obese Zucker 
rat model of type 2 diabetes. We demonstrate for the fi  rst time 
that the sulfur moiety is critical for in vivo pro  tection and iden-
tify HO-1 as a molecular target for active redox compounds.
Our results may help explain why phenolic antioxidants 
like vitamin E have failed to protect against cardiovascular 
disease (2). Thus, the observation that probucol dithiobisphe-
nol, but not probucol bisphenol, inhibited disease in the 
models used here lends support for the notion that the sulfur 
rather than the phenol moieties are critical for protection 
against atherosclerotic vascular disease by redox-active com-
pounds. This notion is consistent with the fi  nding that in the 
rabbit balloon injury model, vitamin E failed to inhibit intimal 
hyperplasia, and it did not promote reendothelialization or 
induce HO-1 in smooth muscle cells. Sulfur atoms commonly 
engage in 2e-oxidation reactions (26), against which phenolic 
radical (i.e., 1e-oxidant) scavengers like probucol bisphenol 
and vitamin E off  er little protection (2, 27). This implies that 
2e-redox reactions may be more important than radical reac-
tions in the pathogenesis of atherosclerotic disease. Indeed, 
2e-oxidant–mediated oxidation of cysteine residues in the 
thiolate form is increasingly linked to the regulation of key 
enzymes (e.g., thioredoxin, Ras GTPases, tyrosine kinases, 
phosphatases, and transcription factors) involved in processes 
central to atherogenesis, such as cell proliferation (28), endo-
thelial function (29), and cell signaling (30). Also, oxidation of 
probucol’s sulfur atoms by 2e-oxidants (27) may relate to both 
the extent to which this antioxidant protects against athero-
sclerosis in Apoe−/− mice (12) and the observed dependency 
of its vascular protection on induction of HO-1.
Compared with inducing HO-1, lowering plasma cho-
lesterol and inhibiting arterial lipid oxidation appear to be of 
lesser importance for probucol’s vascular protection because 
both probucol and probucol dithiobisphenol inhibited lesion 
formation in the models, yet only probucol decreased plasma 
cholesterol. Also, probucol bisphenol lowered plasma cho-
lesterol yet failed to protect in the rabbit restenosis model, 
consistent with the failure of lipid-lowering drugs to decrease 
restenosis after coronary angioplasty in humans (31). Thus, 
hypocholesterolemia can be dissociated from, and is not re-
quired for, the in vivo cardioprotective eff  ect of probucol, as 
shown previously in a rabbit atherosclerosis study (32). The 
observed lack of a high-density cholesterol-lowering eff  ect 
of probucol dithiobisphenol is consistent with a previous re-
port (33). It indicates that this analogue does not share this 
undesirable side eff  ect of the parent drug.
In both Apoe−/− mice and injured rabbits, the proportion 
of aortic lipids present as lipid hydroperoxides (primary pro-
ducts of lipid peroxidation) was unaff  ected by any of the in-
terventions. Similarly, in the rat model of type 2 diabetes, 
probucol did not signifi  cantly alter circulating concentrations 
of F2-isoprostanes, a commonly used marker of (secondary) 
lipid oxidation (25). Thus, inhibition of lipid peroxidation is 
not likely to explain the protective activity of probucol (and 
probucol dithiobisphenol) in the animal models used here, 
consistent with previous studies (9, 12, 14, 34). Because pro-
tection was independent of lipid oxidation, our present results 
do not support the idea that lipoprotein lipid oxidation 
  importantly contributes to atherosclerotic vascular disease. 
Indeed, if lipid oxidation were important in causing disease, 
we would have expected protection to be greatest with pro-
bucol bisphenol and smallest with probucol. This is because 
lipid peroxidation is a radical mediated chain reaction ex-
pected to be inhibited in the order probucol bisphenol > 
probucol dithiobisphenol > probucol, given their respective 
1e-oxidation potentials (Table I). In this context, it is impor-
tant to note that probucol bisphenol accumulated in the aorta 
to concentrations comparable to, if not exceeding those of, 
probucol and probucol dithiobisphenol. Thus, limited acces-
sibility (compared with probucol) cannot explain the failure of 
probucol bisphenol to protect against atherosclerotic disease.
The apparent unimportance of inhibiting aortic lipid per-
oxidation combined with the inability of probucol bisphenol 
to inhibit atherosclerosis and intimal hyperplasia suggests that 
the phenolic moieties are not suffi   cient for vascular protection 
by antioxidants. If so, it helps explain why other phenolic an-
tioxidants, such as α-tocopherol (vitamin E; reference 35) and 
the propane diether analogue of probucol (Table II; reference 
36) do not generally protect against atherosclerosis. This inter-
pretation is supported by the fact that AGI-1067 (i.e., probu-
col with one of its two phenol groups blocked by esterifi  cation 
to succinate; Table II) inhibits atherosclerosis in Apoe−/− and 
in low-density lipoprotein receptor–defi  cient mice (37), and 
restenosis after coronary angioplasty in humans (38).
As indicated, our observation that the sulfur rather than 
phenolic moieties of probucol are important for protection 
suggests that 2e-redox reactions (that sulfur atoms typically 
engage with) are likely important in atherosclerotic diseases. 
There is recent evidence that probucol and probucol dithio-
bisphenol can eff  ectively intercept 2e-oxidant–mediated pro-
cesses. Thus, probucol and probucol dithiobisphenol, but not 
probucol bisphenol, protect against endothelial dysfunction 
induced by the 2e-oxidant hypochlorite (27). Metabolism of 
Table IV.  Blocking heme oxygenase attenuates protection 
by probucol against intimal hyperplasia in obese Zucker rats
Probucol −SnPP-IX
(n = 6)
Probucol +SnPP-IX
(n = 6)
Intimal area (mm2)  0.003 ± 0.002 0.03 ± 0.01a
Medial area (mm2) 0.14 ± 0.0   0.15 ± 0       
Intima-to-media ratio  0.03 ± 0.01 0.24 ± 0.06a
Reendothelialization (%) 93 ± 7  61 ± 7a    
Experimental conditions were essentially as described in the legend to Table III, 
except that in these animals, 10 mg tin protoporphyrin-IX was applied topically 
around the injured artery at the time of surgery, using a pluronic gel (+SnPP-IX) or 
gel alone (−SnPP-IX) as described previously (reference 57). The smaller lesions 
seen here in probucol-treated obese rats −SnPP-IX compared to that shown in 
Table III may be due to different batches of animals used in the two separate 
intervention studies and/or to effects of the gel alone. Values are mean ± SEM.
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probucol to probucol bisphenol and probucol diphenoqui-
none occurs in diseased arteries in vivo. Interestingly, such 
metabolism in vitro is mediated via sulfur oxidation and reca-
pitulated best by 2e-oxidants such as hypochlorite and per-
oxynitrite (27) that are implicated in atherogenesis (2). 
Furthermore, the anti-atherosclerotic activity of probucol in 
aortas of Apoe−/− mice parallels the extent to which the drug 
is metabolized to probucol bisphenol and its diphenoquinone 
(12). Collectively, these fi  ndings suggest that for effi   cient in 
vivo protection, redox-active compounds require an ability 
to intercept 2e-redox reactions that take place during athero-
sclerotic vascular disease and target sulfur atoms, such as pro-
tein cysteine residues. Importantly, the present and previous 
results (12, 27) do not establish that probucol and probucol 
dithiobisphenol themselves intercept relevant 2e-redox reac-
tions in vivo. Indeed, probucol and probucol dithiobisphenol 
react with hypochlorite at rates of  102 M−1 s−1 (27); i.e., 
their ability to scavenge this 2e-oxidant is at best comparable 
to that of other antioxidants, such as ascorbate and vitamin E 
(39, 40). It is therefore most likely that in vivo 2e-redox re-
actions “activate” probucol and probucol dithiobisphenol to 
some important metabolite that then intercepts 2e-redox re-
actions and thus protects against atherosclerotic vascular dis-
ease. The precise identity of the putative metabolite remains 
to be established, although it is clear that probucol bisphenol, 
a known metabolite of probucol, is not generally active in 
protecting against vascular disease.
The proposed ability of probucol’s sulfur atoms to un-
dergo 2e-redox reactions in the artery wall may also be linked 
to the observed dependency of vascular protection on induc-
tion of HO-1. HO-1 is a redox-sensitive enzyme responsive 
to several stress stimulants, including heme, nitric oxide, hyp-
oxia, oxidized low-density lipoprotein, heavy metals, and UV 
light (41). Perhaps most notable, the promoter region of the 
HO-1 gene contains multiple copies of antioxidant response 
elements (ARE) that are critical for enzyme induction (42) 
and that are tightly regulated by the redox-sensitive transcrip-
tion factor NF-E2–related factor 2 (Nrf2). Under resting con-
ditions, Nrf2 is sequestered in the cytosol by the binding of 
Keap1. Upon stimulation, Nrf2 dissociates from Keap1 and 
translocates to the nucleus where it induces HO-1 transcrip-
tion. Interestingly, Nrf2 liberation from Keap1 is regulated by 
redox changes to specifi  c cysteine residues on Keap1 (43, 44) 
so that the putative active probucol metabolite formed by 2e-
redox reactions may induce HO-1 via ARE. Preliminary data 
obtained using a reporter construct indicate that probucol and 
probucol dithiobisphenol do not directly induce ARE-driven 
luciferase in vitro (unpublished data). Furthermore, treatment 
of rabbits with either of the two compounds does not induce 
hepatic glutathione S-transferase, a phase II enzyme known to 
be under the control of ARE, and they do not elevate plasma 
levels of liver enzymes (unpublished data). These fi  ndings in-
dicate that although induction of HO-1 is of central impor-
tance for the protective eff   ects of probucol and probucol 
dithiobisphenol, the precise mechanism underlying this in-
duction remains to be elucidated, although it does not appear 
to represent a global cellular protective mechanism involving 
a general phase II response.
Independently of the mode of its induction, HO-1 is a 
protective enzyme, variously manifested in diff  erent vascular 
cells (41). The protection off  ered by HO-1 induction may be 
based on cellular increases in the concentration of antioxidant 
bile pigments (45) or carbon monoxide (46) and/or a decrease 
in redox-available iron (47). In vascular smooth muscle cells, 
induction of HO-1 stimulates apoptosis (17) and inhibits pro-
liferation and migration (15). In contrast, overexpression of 
HO-1 in endothelial cells protects against apoptosis (17) and 
promotes proliferation (48). These cellular activities of in-
creased HO-1 activity translate into protection against athero-
sclerotic vascular disease. Thus, in animals, increasing HO-1 
activity attenuates atherosclerosis (49, 50), whereas inhibiting 
HO-1 augments disease (51). Also, HO-1 gene delivery in-
hibits neointima formation after vascular injury (15, 52). 
Therefore, the diff  erential eff  ects of probucol (and probucol 
dithiobisphenol) in the rabbit restenosis and rat type 2 diabetes 
models used here are all reminiscent of the actions of HO-1 
in diff  erent animal models of atherosclerotic vascular disease.
The ability to completely block the in vivo protective 
cellular activities of probucol in two diff  erent animal models 
by inhibiting heme oxygenase activity highlights HO-1 as a 
potential therapeutic target in atherosclerotic diseases. Also, it 
suggests that modulation of HO-1 induction in vascular cells 
may be a suitable surrogate in vitro assay to screen for novel 
anti-atherosclerotic agents. In addition, our observations pro-
vide novel and plausible explanations for both the anti-ath-
erosclerotic and anti-restenotic actions of probucol, as well as 
the apparent failure of vitamin E. Finally, our fi  ndings high-
light sulfur moieties as critical for the design of effi   cient re-
dox-active compounds against atherosclerotic vascular disease 
and indicate probucol dithiobisphenol as a lead compound 
for a novel class of therapeutic drugs.
MATERIALS AND METHODS
Materials. Chemicals were obtained from Sigma-Aldrich, except for pro-
bucol (4′,4′-(isopropylidene dithio)bis(2,6,-di-tert-butyl)phenol), which was 
provided by AstraZeneca, Sweden, and probucol dithiobisphenol (4,4′-
  dithiobis(2,6-di-tert-butyl-phenol) and probucol bisphenol (3,3′,5,5′-
tetra-tert-butyl-4,4′-bisphenol), which were obtained from Polysciences. 
Hydroperoxides of cholesteryllinoleate were prepared as described   previously 
(53). 3,3′,5,5′-tetra-tert-butyl-4,4′-diphenoquinone (diphenoquinone) was 
prepared from probucol bisphenol (54).
Determination of redox potentials. Redox potentials were determined 
for analytical samples of probucol, probucol dithiobisphenol, and probucol 
dithiobisphenol (Polysciences) by cyclic voltammetry using a BAS electro-
chemical analyzer as described previously (55).
Animal models. Four groups of 8–10-wk-old male Apoe−/− mice (Animal 
Resources Centre, Perth, Australia) were fed a high-fat diet based on Harlan 
Teklad diet TD88137 (9) ± 1% (wt/wt) probucol, 0.02% probucol dithio-
bisphenol, or 0.02% probucol bisphenol for 5 mo. Tissue harvesting and an-
alyses were performed as described previously (9, 12), using 15 and 10 mice 
in each group for biochemical and histological analyses, respectively.
For the rabbit aortic balloon injury model, four groups of male New 
Zealand White rabbits (1.8–2.2 kg; Merunga Farm) were matched for body 
weight and baseline plasma cholesterol, and fed 100 g per day of normal JEM VOL. 203, April 17, 2006  1125
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chow ± 1% (wt/wt) probucol, 0.02% probucol dithiobisphenol, or 0.02% 
probucol bisphenol (wt/wt) for up to 9 wk with water provided ad libitum. 
Experiments comparing probucol and vitamin E used three groups of rabbits 
fed normal chow ± 1% (wt/wt) α-tocopheryl acetate or 1% probucol (wt/wt) 
for 6 wk. Aortic balloon injury to achieve complete endothelial denudation 
was performed at the end of week 3 (14). The harvesting of aortas (14) was 
performed after an additional 4 d (n = 8 per group) or 6 wk (n = 6 per 
group). Three separate groups of rabbits (n = 6 per group) on normal chow 
± 1% probucol or 0.02% probucol dithiobisphenol received intraperitoneal 
injection of tin(IV) protoporphyrin-IX dichloride (7.5 mg/kg; Frontier 
  Scientifi  c) every other day (56) for the entire 9-wk period. None of the 
treatments aff  ected the body weight of the animals.
For the type 2 diabetes model, 11–13-wk-old lean and obese Zucker rats 
(n = 6–9 per group) were obtained from Monash Animal Services.   Animals 
were fed chow with or without added probucol 1% (wt/wt) for 2 wk before 
balloon injury of the left common carotid artery (22). Complete endothelial 
denudation was confi  rmed for both lean and obese rats with   Evan’s Blue 
staining immediately after balloon injury in a pilot study. For in vivo inhibi-
tion of HO-1, 10 mg tin(IV) protoporphyrin-IX (Porphyrin   Products) was 
applied topically around the injured artery at the time of surgery, using a plu-
ronic gel (BASF) or gel alone (controls), as described previously (57). After 
injury, the external carotid artery was ligated, and animals were fed their re-
spective diet for another 2 wk. The University of New South Wales Animal 
Care & Ethics Committee approved all animal studies reported here.
Lesion assessment and immunohistochemistry. In Apoe−/− mice, le-
sion areas were determined in the aortic arch (50), descending thoracic, and 
abdominal aorta (12). In rabbits, aortic lesion assessment was performed at 
the third pair of lumbar arteries as described previously (14, 16). In Zucker 
rats, 5-μm-thick transverse cross sections were obtained from the mid-third 
of the common carotid artery (n = 3 per animal). Immediately adjacent sec-
tions were used for immunohistochemistry, using Mac-3 (macrophages, di-
lution 1:200; DakoCytomation), PCNA (cell proliferation, dilution 1:500; 
DakoCytomation), von Willebrand Factor or CD31 (endothelium, dilution 
1:200 or 1:50; DakoCytomation), anti–rat HO-1 monoclonal (dilution 1:50; 
Santa Cruz Biotechnology, Inc.), and polyclonal (dilution 1:2,000; Stress-
Gen Biotechnologies) antibodies with avidin-biotin–horseradish peroxidase 
for signal detection (Vectorstain Elite ABC kit; Vector Laboratories). Apop-
tosis was assessed using the TUNEL assay kit (Roche) according to the 
  manufacturer’s instructions. Digital images were taken for quantitative 
morphometric analysis. Intimal, medial, and Mac-3+ areas were determined 
using Adobe Photoshop V6.0 by tracing (9, 51). Reendothelialization was 
determined in longitudinal sections as the distance of CD31+ cells from the 
branch orifi  ce and in cross sections as the percentage of cells positive for von 
Willebrand Factor from the circumference of lumen using Scion Image 
  Software. For experiments with vitamin E, Evans blue was injected intrave-
nously at week 6 just before aorta harvesting, and reendothelialization 
was determined by the extent of denuded (blue) versus reendothelialized 
(white) areas from photographs of the en face aortas (14). Total cell profi  les, 
TUNEL+ cells, and PCNA+ cells were counted manually at a high magnifi  ca-
tion (40× objective). The extent of intimal hyperplasia was expressed as the 
intima-to-media ratio. A single operator using coded samples performed all 
analyses blinded.
Biochemical analyses. Fresh whole blood obtained when animals were 
killed was used to measure blood glucose and glycosylated hemoglobin us-
ing a standardized portable glucometer (Roche) and the Hemoglobin A1c 
Reagent kit (DCA 2000), respectively. Plasma was obtained by centrifuging 
the EDTA blood (1,000 g at 4°C for 10 min) and was then stored at −80°C 
until used. The profi  le of lipoproteins was determined by FPLC (58) from 
pooled plasma of 10 mice of each group. Plasma triglycerides were quanti-
fi  ed using an Infi  nity Triglycerides kit (Sigma-Aldrich). Plasma F2-isopros-
tanes and arachidonic acid were determined by stable isotope dilution gas 
chromatography-mass spectrometry (59) and gas chromatography (60), re-
spectively, as described previously (59). Plasma cholesterol was determined 
by HPLC after organic extraction of individual plasma samples, as described 
previously (12).
For aortic materials, entire aortas from fi  ve mice or individual 2-cm 
segments of the abdominal aorta at the celiac artery from rabbits were used. 
The aortic segments were homogenized and extracted (61), and the organic 
phase was analyzed by HPLC with UV (for cholesterol and nonoxidized 
neutral lipids, cholesterylesters plus triglycerides) and postcolumn chemilu-
minescence detection (for hydroperoxides of the neutral lipids; references 
62 and 63). Probucol, probucol dithiobisphenol, probucol bisphenol, and 
probucol diphenoquinone were analyzed by gradient RP-HPLC (53). 
All compounds were quantifi  ed by area comparison using authentic standards.
Heme oxygenase. For HO-1 expression, rabbit aortic smooth muscle cells 
(Cell Applications) (passages 6–11) were cultured in 12-well plates until 
60–70% confl  uent as described previously (16). Cells were then incubated 
for 24 h in DMEM containing 0.2% fetal calf serum and 0.3% BSA with-
out or with added probucol (50-μM fi  nal concentration) or α-tocopherol 
(vitamin E, 50 μM). Total RNA was extracted by directly adding TRIzol 
reagent (Invitrogen) to the cells according to the manufacturer’s instruc-
tions. For tissue, total RNA was isolated with TRIzol as described previ-
ously (16). Corresponding cDNA was prepared using the Superscript III fi  rst 
strand synthesis kit (Invitrogen). Real-time PCR was performed using an 
ABI PRISM 7700 Sequence Detection System with the SYBR Green PCR 
Master Mix (Applied Biosystems). Hydroxymethylbilane synthase (HMBS) 
was used to normalize RNA quantity, using the following PCR primers: 
HMBS forward, 5′-G  A  G  T  G  A  T  T  C  G  C  G  T  G  G  G  T  A  C  C  -3′; HMBS reverse, 
5′-G  G  C  T  C  C  G  A  T  G  G  T  G  A  A  G  C  C  -3′. The primers for HO-1 were: for-
ward, 5′-T  G  G  A  G  C  T  G  G  A  C  A  T  G  G  C  C  T  T  C  -3′; reverse, 5′-T  C  T  G  G  G  C-
G  A  T  C  T  T  C  T  T  A  A  G  G  -3′. The amount of HO-1 mRNA was determined 
relative to HMBS mRNA using the comparative CT method described in 
the ABI 7700 Sequence Detector User Bulletin 2. PCR products were 
verifi  ed by sequence analysis. Heme oxygenase activity was determined 
in microsomes prepared from homogenized aortic tissue and assessed by 
HPLC as described previously (16).
Vascular reactivity. 3-mm segments of the abdominal aorta at the second 
pair of lumbar arteries from rabbits were used for isometric tension experi-
ments, with relaxation of preconstricted segments (to 80% maximal contrac-
tion) monitored (14). Segments extending proximally were analyzed for 
guanosine 3′,5′-cyclic monophosphate content as an index of nitric oxide 
synthase activity (14, 64).
Statistics. Data are expressed as mean ± SEM. One-way ANOVA and the 
student-Newman-Keul’s test were used to evaluate diff  erences  between 
groups, whereas acetylcholine and sodium nitroprusside dose responses 
curves were compared by two-way ANOVA for repeated measures, with 
P < 0.05 considered signifi  cant.
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